EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT

Immune analysis of lymph nodes in relation to thepresence or absence of tumor infiltrating lymphocytes intriple-negative breast cancer

A phase 2 study of chemotherapy de-escalation using a pathological response-guided strategy in patients with HER2-positive, low-risk early breast cancer: PHERGain-2

Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects

Pembrolizumab plus eribulin in hormone-receptore positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label,multicentre, single-arm, phase II trial

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive or HER2-low-expressing advanced breast cancer and central nervous system involvement: Preliminary results from the DEBBRAH phase 2 study

Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor–Positive,ERBB2-Negative Advanced Breast Cancer A Randomized Clinical Trial

First-line osimertinib in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met

PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients

Metaformin in the prevention of hyperglycemia in patients with PIK#CA-mutated, hormone receptor (HR)[+]/HER2[-] advanced breast cancer treated with alpelisib plus fulvestrant: METALLICA study

The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers

Nobody dares stopping clinical research, not even COVID-19

CDK4/6 inhibitors in breast cancer: spotting the difference